Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure

Details for Australian Patent Application No. 2005304421 (hide)

Owner CV Therapeutics, Inc.

Inventors Blackburn, Brent; Sabbah, Hani

Agent Freehills

Pub. Number AU-A-2005304421

PCT Pub. Number WO2006/053161

Priority 60/626,154 09.11.04 US

Filing date 9 November 2005

Wipo publication date 18 May 2006

International Classifications

A61K 31/495 (2006.01) - having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

Event Publications

24 May 2007 Amendment Made

  The nature of the amendment is: Amend the invention title to read Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure

31 May 2007 PCT application entered the National Phase

  PCT publication WO2006/053161 Priority application(s): WO2006/053161

22 October 2009 Alteration of Name

  The name of the applicant has been altered to Gilead Palo Alto, Inc.

2 June 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005304422-PTPase inhibitors and T-cell activators for treating cancer

2005304420-Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases